MiR-216a-5p inhibits proliferation, migration, and enhances oxaliplatin sensitivity by targeting ZBTB2 in gastric cancer cells
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.MicroRNA-216a-5p suppresses gastric cancer (GC) by inhibiting cell growth and oxaliplatin (OXA) resistance. This study identifies miR-216a-5p as a potential therapeutic target for improving GC chemotherapy efficacy.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- MicroRNA-216a-5p (miR-216a-5p) is implicated in tumor progression and chemoresistance.
- Its precise role and mechanisms in gastric cancer (GC) remain unclear.
Purpose Of The Study
- To investigate the function of miR-216a-5p in GC progression.
- To determine its impact on oxaliplatin (OXA) resistance in GC.
Main Methods
- Assessed miR-216a-5p expression in GC tissues and cell lines using qRT-PCR.
- Identified and validated ZBTB2 as a direct target of miR-216a-5p via bioinformatics, dual-luciferase reporter assays, RNA immunoprecipitation, and Western blot.
- Conducted in vitro and in vivo functional assays to evaluate the effects of miR-216a-5p and ZBTB2 on GC cell behavior and drug sensitivity.
Main Results
- miR-216a-5p was significantly downregulated in GC samples and cell lines.
- Overexpression of miR-216a-5p inhibited GC cell proliferation and migration and increased OXA sensitivity.
- miR-216a-5p directly targets ZBTB2, suppressing GC growth and chemoresistance.
- ZBTB2 overexpression partially reversed the effects of miR-216a-5p, confirming the regulatory axis.
Conclusions
- miR-216a-5p acts as a tumor suppressor in GC by inhibiting proliferation, migration, and OXA resistance via ZBTB2 downregulation.
- miR-216a-5p represents a promising molecular target for enhancing chemotherapy efficacy in GC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
